Trials / Completed
CompletedNCT01229423
Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Allergan · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of LATISSE® (bimatoprost 0.03%) in the augmentation of eyelashes in Korean women.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bimatoprost 0.03% | One drop of bimatoprost 0.03% (LATISSE®) applied evenly to each upper eyelid in the evening. Treatment is once daily for up to 40 weeks. |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2010-06-01
- Completion
- 2010-10-01
- First posted
- 2010-10-27
- Last updated
- 2019-01-29
- Results posted
- 2012-01-23
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01229423. Inclusion in this directory is not an endorsement.